Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares

Key Points

• Insider sale: Avalo insider Mittie Doyle sold 679 shares on April 1 at an average of $16.00 for $10,864, reducing her holding to 3,622 shares (a 15.79% decrease); the sale was executed under a pre-arranged Rule 10b5-1 plan and follows a March 16 sale of 25,492 shares for ~$411,696.
• Earnings beat: Avalo reported Q1 EPS of ($0.37), beating the consensus of ($1.54) with revenue of $0.06M, though analysts still project a substantially negative full-year EPS (consensus -19.07).
• Stock and analyst backdrop: Shares traded near $17.76 with a $404.8M market cap and a 1-year range of $3.39–$20.72; Wall Street consensus is a Moderate Buy with an average price target of $42.25 and mostly Buy ratings but one Sell.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $16.00, for a total transaction of $10,864.00. Following the completion of the transaction, the insider owned 3,622 shares in the company, valued at $57,952. This represents a 15.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80.

Avalo Therapeutics Stock Performance

NASDAQ AVTX remained flat at $17.76 during midday trading on Friday. The company's stock had a trading volume of 1,109,141 shares, compared to its average volume of 845,897. Avalo Therapeutics, Inc. has a 1-year low of $3.39 and a 1-year high of $20.72. The firm has a 50 day simple moving average of $15.50 and a 200-day simple moving average of $15.91. The stock has a market capitalization of $404.75 million, a P/E ratio of -3.10 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analysts' expectations of ($0.21) million. As a group, research analysts anticipate that Avalo Therapeutics, Inc. will post -19.07 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Mizuho raised shares of Avalo Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. BTIG Research reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, March 24th. HC Wainwright upped their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, March 25th. Finally, Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a "buy" rating and a $50.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $42.25.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors have recently bought and sold shares of AVTX. Caligan Partners LP acquired a new position in Avalo Therapeutics in the 3rd quarter valued at about $10,592,000. Balyasny Asset Management L.P. acquired a new position in Avalo Therapeutics in the third quarter valued at approximately $10,390,000. Vanguard Group Inc. grew its position in Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company's stock worth $8,803,000 after acquiring an additional 525,696 shares during the period. Millennium Management LLC grew its position in Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company's stock worth $11,985,000 after acquiring an additional 522,548 shares during the period. Finally, Jennison Associates LLC acquired a new stake in Avalo Therapeutics during the fourth quarter worth $8,637,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.